← Leaderboards
Seyed Javad Mirhassani Moghaddam
University Of Tx Md Anderson Can Ctr
$4,738,281
Attributed
$8,100,544
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,100,544 · 4
By mechanism
R01$8,100,544 · 4
Top collaborators
- Humam Kadara9 shared
- Ferdinandos Skoulidis2 shared
- David John Tweardy2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Humam Kadara$4,695,975
- Don Lynn Gibbons$4,258,623
- Courtney Dinardo$2,316,391
- Kapil N. Bhalla$16,921,043
- Khandan Keyomarsi$13,000,468
Others in their field
Other Emerging Leaders on “Signal Transduction”
- Yunda Huang · Fred Hutchinson Cancer Center$53,064,276
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Leonard Freedman · Leidos Biomedical Research, Inc.$32,575,497
- Bala Raja · Luminostics, Inc.$28,624,460
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
Research focus
Signal TransductionMalignant Neoplasm Of LungLungTumorMediatingMutantMouse ModelProgramsPreventSmokerPhenotypeInflammatoryInflammationInsightImmuneResponsePathway InteractionsMolecularImmunotherapyEventInterleukin-6MutationLung NeoplasmsMalignant Neoplasms
Grant awards (16)
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor$671,795
R01 · FY2025 · CA
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$613,551
R01 · FY2025 · CA
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$393,023
R01 · FY2025 · CA
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor$672,297
R01 · FY2024 · CA
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$593,147
R01 · FY2024 · CA
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$532,609
R01 · FY2024 · CA
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$586,157
R01 · FY2023 · CA
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$520,592
R01 · FY2023 · CA
Elucidating the evolution of Krt8+ alveolar cells to Kras-mutant lung preneoplasia and cancer$596,247
R01 · FY2022 · CA
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$540,668
R01 · FY2022 · CA
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling$358,434
R01 · FY2022 · CA · contact PI
Interplay between host microbiome and immunomodulatory responses in the pathogenesis of Kras mutant lung cancer$556,410
R01 · FY2021 · CA
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling$365,756
R01 · FY2021 · CA · contact PI
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling$367,325
R01 · FY2020 · CA · contact PI
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling$360,787
R01 · FY2019 · CA · contact PI
Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling$371,746
R01 · FY2018 · CA · contact PI